A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Model scores of the 29,894 trials active now.

Model score 38% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiaamlchemotherapypatientrefractory
  Phrases that lowered it: efficacygrowthto evaluateevaluate thesafety
• Sponsor's past termination rate: 83.3% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 20967 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 14.4% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 1 (raises risk) · Who can join
• Drug's FAERS reports before start: 107875 (lowers risk) · Drug's FDA history
• Keywords listed: 13 (raises risk) · Design
• Sponsor's past trials: 6 (raises risk) · Sponsor's track record
• Maximum age: 21 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 66.9% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AC220 for Children With Relapsed/Refractory ALL or AML NCT01411267 · started 2011 · scored riskier than 99% of active trials completed
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia NCT02303821 · started 2015 · scored riskier than 68% of active trials completed
• Epigenetic Reprogramming in Relapse/Refractory AML NCT03263936 · started 2017 · scored riskier than 99% of active trials completed
• Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia NCT01743807 · started 2014 · scored riskier than 96% of active trials terminated
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma NCT01614197 · started 2015 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.